Prognostic value of PDCD-1 and CTLA-4 in ovarian cancer patients

Abstract

Therapeutic effectiveness of treatments for ovarian cancer is not optimal. PDCD-1 and CTLA-4 offers the potential as a prognostic marker in addition to being a target for therapy. To assess the prognostic roles of PDCD-1 and CTLA-4 Gene in ovarian cancer, we utilized the Kaplan Meier plotter, a biomarker assessment tool with large quantities of data. The relationship between PDCD-1 and overall survival (OS) as well as CTLA-4 and OS were presented using Hazard Ratio, 95% CI and logrank P value. Then gene expression level was compared using H-Test and U test. The results were as follows: PDCD-1 and CTLA-4 gene expressions among 1582 ovarian cancer patients were shown with median gene expression value as the cut-off. Expression of PDCD-1 and CTLA-4 did not differ with regard to stages and P53 gene mutation. But the expression of CTLA-4 was higher in endometrioid than in serous cancer patients. Different grades of both PDCD-1 and CTLA-4 had different mean values. Higher expression of the PDCD-1 was not significantly correlated with better OS with HR 0.88 (95% CI: 0.77-1.01, P=0.061) but higher CTLA-4 was associated with better survival with HR 0.84 (95% CI: 0.73-0.96, P=0.0099) on the transcriptome level. In conclusion, lower expression of CTLA-4, but not PDCD-1 predicts worse survival.